select a format

Single User License
USD 250 INR 16065
Site License
USD 500 INR 32130
Corporate User License
USD 750 INR 48195

Alternatively

Request a quote
Request a Customized research
Request for Sample Report





Recent Viewed Reports


Why Ken Reasearch?


Testimonials

This is with regards to your report on India PVC pipes and fitting market outlook industry outlook to 2019. This is a very well written report and accept my compliments on the same.... ... "Mohit Mittal, Consultant, KPMG Advisory Services"

I am pleased to see the very useful and productive information in the report..Very well structured great presentation reflect professionalism in your research studies.... "Mustafa Masood, Financial Analyst , Coldwell Banker Riyadh"

While we still are studying and analysing your reports about Vietnam & Thailand, we would like to convey to your research team that they have done a very good job in compiling so much of information together. We hope to see more of such well researched reports. All the best & keep it up. ... "Prashant Bhagwat,General Manager, Mahindra"

We would like to appreciate Ken Research for their great efforts and wonderful support in providing the Market Intelligence Report for ITPC. The information, statistics and research are well understandable and very clear to the point. We are happy with Ken research for their good client service, on-time delivery of the report and as said the report itself. Thank you Ken research for bringing the valuable output for us. We would be looking forward to have more research with you in the near future. Wish you a success in your business!... "Jestin Mathew, Indonesian Trade Promotion Center"

The Report was very interesting and useful for me... "Marketing Manager, Western Union Business Solutions"


Aeglea BioTherapeutics Inc (AGLE)-Pharmaceuticals & Healthcare-Deals and Alliances Profile

Aeglea BioTherapeutics Inc (AGLE)-Pharmaceuticals & Healthcare-Deals and Alliances Profile


  • Products Id :- GDPH500853D
  • |
  • Pages: 38
  • |
  • April 2017
  • |
  • |
  Request for Sample Report

Executive Summary

Aeglea BioTherapeutics Inc (Aeglea BioTherapeutics), formerly Aeglea BioTherapeutics Holdings, LLC is a biotechnology company that develops and commercializes engineered human enzymes for the treatment of cancer and rare genetic diseases. The company's product pipeline comprises AEB1102, AEB3103, AEB2109, and AEB4104. It develops engineered human enzymes to target and degrade amino acids in the blood. Aeglea BioTherapeutics is developing products for the treatment of Arginase I Deficiency; homocystinuria and others. The company works in partnership with research institutions, allied healthcare providers and pharmaceutical companies to discover, develop and market new product candidates. Aeglea BioTherapeutics is headquartered in Austin, Texas, the US.

Aeglea BioTherapeutics Inc (AGLE)-Pharmaceuticals & Healthcare-Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

Financial Deals-Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.

Deals by Year-Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.

Deals by Type-Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.

Deals by Region-Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.

Deals by Sub-sector-Chart and table showing information on the number of deals and value reported by the company, by sub-sector.

Major Deals-Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company's (major public companies) key financial metrics and ratios.

Business Description-A brief description of the company's operations.

Key Employees-A list of the key executives of the company.

Important Locations and Subsidiaries-A list and contact details of key centers of operation and subsidiaries of the company.

Key Competitors-A list of the key competitors of the company.

Key Recent Developments-A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements

The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company's business segments' expansion / divestiture strategy

The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy.

Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company

Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios.

Equip yourself with detailed information about the company's operations to identify potential customers and suppliers.

The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company

Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research

Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.



Contact Us:
Ken Research
Ankur Gupta, Head Marketing & Communications
ankur [@] kenresearch.com
+91-9015378249
www.kenresearch.com

Table of Contents

Table of Contents 2

List of Tables 4

List of Figures 5

Aeglea BioTherapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 6

Aeglea BioTherapeutics Inc, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 7

Aeglea BioTherapeutics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 8

Aeglea BioTherapeutics Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2011 to YTD 2017 9

Aeglea BioTherapeutics Inc, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 10

Aeglea BioTherapeutics Inc, Pharmaceuticals & Healthcare, Deal Details 11

Venture Financing 11

Aeglea BioTherapeutics Raises USD44 Million in Series B Financing 11

Aeglea BioTherapeutics Raises Additional USD1 Million in Series A Venture Financing 12

Aeglea BioTherapeutics Raises US$5.1 Million In Venture Financing 13

Licensing Agreements 13

AEMase Enters into Licensing Agreement with University of Texas at Austin 13

AECase Enters into Licensing Agreement with University of Texas at Austin 14

Equity Offering 15

Aeglea BioTherapeutics Raises USD54.8 million in IPO 15

Aeglea BioTherapeutics Inc-Key Competitors 17

Key Employees 18

Locations And Subsidiaries 19

Head Office 19

Other Locations & Subsidiaries 19

Recent Developments 20

Financial Announcements 20

Mar 23, 2017: Aeglea BioTherapeutics Provides Corporate Update and Reports Fourth Quarter and Full Year 2016 Financial Results 20

Nov 09, 2016: Aeglea BioTherapeutics Provides Corporate Update and Reports Third Quarter 2016 Financial Results 22

Aug 09, 2016: Aeglea BioTherapeutics Announces Second Quarter 2016 Financial Results 24

May 19, 2016: Aeglea BioTherapeutics Announces First Quarter 2016 Financial Results 26

Corporate Communications 27

Feb 16, 2017: Aeglea BioTherapeutics Appoints Dr. Suzanne Bruhn to Board of Directors 27

May 16, 2016: Aeglea BioTherapeutics Names Dr. Sandra Rojas-Caro as Chief Medical Officer 28

Mar 15, 2016: Aeglea BioTherapeutics Appoints Dr. Anthony Quinn to Board of Directors 29

Product News 30

11/08/2016: Aeglea BioTherapeutics to Present a Poster at the Society for Immunotherapy of Cancer 2016 Annual Meeting Suggesting Potential for AEB1102 Combination Therapy with Immuno-Oncology Checkpoint Inhibitors 30

Product Approvals 31

May 23, 2016: Aeglea BioTherapeutics Receives FDA Fast Track Designation for AEB1102 for the Treatment of Patients with Hyperargininemia Secondary to Arginase I Deficiency 31

Mar 14, 2016: Aeglea BioTherapeutics Announces FDA Acceptance of its Investigational New Drug Application for AEB1102 for the Treatment of Hematological Malignancies 32

Jan 07, 2016: Aeglea BioTherapeutics Announces FDA Acceptance of Its Investigational New Drug Application for AEB1102 for the Treatment of Arginase I Deficiency 33

Clinical Trials 34

Sep 15, 2016: Aeglea BioTherapeutics Doses First Patients in Phase 1 Trial of AEB1102 for the Treatment of Arginase I Deficiency 34

Aug 29, 2016: Aeglea BioTherapeutics Doses First Patient in Phase 1 Trial of AEB1102 for the Treatment of Hematological Malignancies 35

Jul 18, 2016: Aeglea BioTherapeutics Provides Update on AEB1102 Clinical Program in Rare Diseases and Cancer 36

Appendix 38

Methodology 38

About GlobalData 38

Contact Us 38

Disclaimer 38

List of Figures

Aeglea BioTherapeutics Inc, Pharmaceuticals & Healthcare, Deals by Type, 2011 to YTD 2017 1

Aeglea BioTherapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 1

Aeglea BioTherapeutics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 1

Aeglea BioTherapeutics Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2011 to YTD 2017 1

Aeglea BioTherapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 6

Aeglea BioTherapeutics Inc, Pharmaceuticals & Healthcare, Deals by Type, 2011 to YTD 2017 7

Aeglea BioTherapeutics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 8

Aeglea BioTherapeutics Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2011 to YTD 2017 9

List of Tables

Aeglea BioTherapeutics Inc, Pharmaceuticals & Healthcare, Key Facts, 2016 1

Aeglea BioTherapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 6

Aeglea BioTherapeutics Inc, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 7

Aeglea BioTherapeutics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 8

Aeglea BioTherapeutics Inc, Deals By Therapy Area, 2011 to YTD 2017 9

Aeglea BioTherapeutics Inc, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 10

Aeglea BioTherapeutics Raises USD44 Million in Series B Financing 11

Aeglea BioTherapeutics Raises Additional USD1 Million in Series A Venture Financing 12

Aeglea BioTherapeutics Raises US$5.1 Million In Venture Financing 13

AEMase Enters into Licensing Agreement with University of Texas at Austin 13

AECase Enters into Licensing Agreement with University of Texas at Austin 14

Aeglea BioTherapeutics Raises USD54.8 million in IPO 15

Aeglea BioTherapeutics Inc, Key Competitors 17

Aeglea BioTherapeutics Inc, Key Employees 18

Aeglea BioTherapeutics Inc, Subsidiaries 19

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to query [@] kenresearch.com
 


Ken Research Pvt. Ltd. 27A, Tower B-2, Spaze I Tech Business Park, Sohna Road, sector 49
     Gurgaon, Haryana - 122001, India
+91 1244230204

download

Company Brochure

Engage with Us

query [@] kenresearch.com